MoonLake Immunotherapeutics/$MLTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Primary listing
Employees
100
Headquarters
Zug, Switzerland
Website
MLTX Metrics
BasicAdvanced
$759M
-
-$3.33
1.24
-
Price and volume
Market cap
$759M
Beta
1.24
52-week high
$62.75
52-week low
$5.95
Average daily volume
9M
Financial strength
Current ratio
8.502
Quick ratio
7.949
Long term debt to equity
25.491
Total debt to equity
26.006
Interest coverage (TTM)
-43.62%
Profitability
EBITDA (TTM)
-226.967
Effective tax rate (TTM)
-0.19%
Management effectiveness
Return on assets (TTM)
-30.72%
Return on equity (TTM)
-54.33%
Valuation
Price to book
2.34
Price to tangible book (TTM)
2.34
Price to free cash flow (TTM)
-3.616
Free cash flow yield (TTM)
-27.65%
Free cash flow per share (TTM)
-2.94
Growth
Earnings per share change (TTM)
155.96%
3-year earnings per share growth (CAGR)
4.66%
Bulls say / Bears say
Merck engaged in nonbinding talks to acquire MoonLake for over $3 billion, signaling strong strategic interest in MoonLake’s SLK platform ahead of its late-stage clinical readouts (Reuters).
MoonLake secured a $500 million non-dilutive term loan facility with Hercules Capital, which, alongside its cash balance, extends its projected cash runway into 2028, providing financial flexibility and insulation from market volatility (SEC).
The company’s diversified clinical pipeline remains on track for multiple catalysts, including an earlier-than-expected interim readout from the Phase 2 PPP trial and a pivotal Phase 3 HS primary endpoint data readout expected around September 2025, supporting a stable development trajectory across indications (GlobeNewswire).
Sonelokimab failed to meet the primary endpoint in one of two pivotal Phase 3 hidradenitis suppurativa trials, with the VELA-2 study narrowly missing statistical significance, triggering an 88% share price collapse on disappointing efficacy data (Barron's).
A securities class action lawsuit filed after the Phase 3 data release alleges that MoonLake misled investors regarding SLK’s purported clinical advantages over existing monoclonal antibodies, exposing the company to significant legal liabilities and potential damages (PRNewswire).
Mixed Phase 3 results have undermined regulatory confidence, as only one of two VELA trials met its endpoint, raising the likelihood that regulators may require additional confirmatory studies before approving sonelokimab, potentially delaying the BLA submission and commercialization timeline (S&P Global).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
MLTX News
AllArticlesVideos
MLTX DEADLINE: MoonLake Immunotherapeutics Investors with Losses are Notified to Contact BFA Law before December 15 Securities Class Action Deadline
Newsfile Corp1 hour ago
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Newsfile Corp1 day ago
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at MoonLake Immunotherapeutics
Business Wire2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $759M as of November 08, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of November 08, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.